Hamburg

• Evaluation of Safety, Tolerability, and Pharmacodynamic Effects of Topically Applied SUDO-286 in Psoriasis Ended
  2023-509079-18-00 3 2024-07-22 Plaque Psoriasis
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop … Ended
  2023-506558-20-00 5 2024-06-26 Dermatitis atopic
• A randomized, multicenter, open-label trial comparing the effectiveness of Inclisiran to bempedoic acid on LDL cholesterol (LDL-C) lowering … Ended
  2024-511076-32-00 6 2024-06-21 Hypercholesterolemia
• Evaluation of irritation potential of topical formulations on intact skin Ended
  2024-511826-29-00 3 2024-06-20 Dermal tolerability test: Testing for non-specific, local irritating r
• A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT) Ended
  2023-507410-27-00 4 2024-06-19 Severe Asthma
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory col … Ended
  2023-509771-17-00 10 2024-06-04 Metastatic Colorectal cancer (mCRC)
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2022-501196-41-00 5 2024-05-29 Dermatitis atopic
• A Phase 3, Randomized, Crossover, Open-Label, Active-Controlled Study of Sepiapterin versus Sapropterin in Participants With Phenylketonuria … Ended
  2023-506238-61-00 5 2024-05-10 Phenylketonuria
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject … Ended
  2023-505842-24-00 5 2024-05-07 Moderate to Severe Plaque Psoriasis
• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended
  2022-502899-23-00 5 2024-04-23 Hepatic Encephalopathy (OHE)
• A Study of Nicotine Freshmint Mouthspray in E-cigarette Users Willing to Quit Ended
  2023-505036-35-00 5 2024-04-23 Vaping cessation in e-cigarette users
• A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metast … Ended
  2023-505257-40-00 9 2024-04-17 metastatic esophagogastric adenocarcinoma (Stage IV)
• Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis Ended
  2023-510127-30-00 1 2024-04-17 Relapsing Remitting Multiple Sclerosis (RRMS)
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet … Ended
  2023-505414-15-00 4 2024-04-10 Dermatitis, Atopic
• A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi … Ended
  2022-501421-20-00 5 2024-04-09 Gout with hyperuricemia
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to … Ended
  2023-504564-42-00 4 2024-04-08 Moderate to Severe Rheumatoid Arthritis
• A study to learn about how elinzanetant works and how safe it is in women having sleep disturbances associated with menopause Ended
  2023-504955-28-01 4 2024-03-14 Sleep disturbances associated with menopause
• A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W … Ended
  2023-507206-13-00 5 2024-03-14 Type 2 Diabetes
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• Study on immunogenicity and safety of a meningococcal ACYW conjugate vaccine in healthy infants and toddlers Ended
  2023-508177-85-00 5 2024-03-12 Healthy volunteers (Meningococcal infection)
• A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 … Ended
  2023-506092-10-00 4 2024-03-11 Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous
• A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended
  2023-503910-60-00 4 2024-03-05 Rheumatoid arthritis
• A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended
  2023-505396-71-00 4 2024-03-01 Early Alzheimer’s Disease with Biomarkers of Inflammation

Showing 865–888 of 1,087 trials